Companies › Skye Bioscience
1 active drug program in 2 registered trials: 2 Phase 2; Metabolic and endocrine; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Nimacimab Cannabinoid CB1 receptor negative allosteric modulator | CNR1 | Phase 2 | Obesity | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06577090 | Nimacimab | Phase 2 | Obesity | Metabolic and endocrine | Nov 2026 |
| NCT06577090 | Nimacimab | Phase 2 | Obesity | Metabolic and endocrine | Nov 2026 |
Cash and short-term investments of $10m on 2026-06-30; operating cash outflow about $32m a year; runway about 4 months at that burn, to Oct 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Jazz Pharmaceuticals IGC Pharma Sinfatin Zynerba Pharmaceuticals PleoPharma Laboratorio Elea Phoenix Bazelet Nehushtan Incannex Healthcare Vertanical Alasht Pharmed
Veru Actimed Therapeutics PolTREG Protalix Verdiva Bio Dev
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.